

Journal Club April 2023

Termin: 06.04.2023
Klinischer Teil: Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
DOI: [https://doi.org/10.1016/S0140-6736\(21\)00592-4](https://doi.org/10.1016/S0140-6736(21)00592-4)
Referent/in: offen

Wissenschaftlicher Teil: Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study
DOI: <https://doi.org/10.1182/bloodadvances.2021005725>
Referent/in: Prof. Dr. med. Sebastian Böttcher

Termin: 13.04.2023
Klinischer Teil: Fallpräsentation
DOI: entfällt
Referent/in: Dr. med. Ursula Kriesen

Wissenschaftlicher Teil: HNSCC-CMTM6 BiomarkerStudie - HRO Kollektiv
DOI: entfällt
Referent/in: Dr. Anne-Sophie Becker (IPath)

Termin: 20.04.2023
Klinischer Teil: Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension
DOI: <https://doi.org/10.1056/NEJMoa2212663>
Referent/in: Viktoria Zink

Wissenschaftlicher Teil: Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
DOI: <https://doi.org/10.1182/blood.2022016090>
Referent/in: Dr. rer. hum. Anna Richter

Termin: 27.04.2023
Klinischer Teil: Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy
DOI: <https://doi.org/10.1007/s00277-023-05088-7>
Referent/in: Johannes Lakner

Wissenschaftlicher Teil: Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
DOI: <https://doi.org/10.1158/0008-5472.CAN-21-4309>
Referent/in: Larissa Lechermeier (UKJ)